[go: up one dir, main page]

UY27378A1 - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
UY27378A1
UY27378A1 UY27378A UY27378A UY27378A1 UY 27378 A1 UY27378 A1 UY 27378A1 UY 27378 A UY27378 A UY 27378A UY 27378 A UY27378 A UY 27378A UY 27378 A1 UY27378 A1 UY 27378A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
compositions
steroid
subcutaneous
administration
Prior art date
Application number
UY27378A
Other languages
English (en)
Inventor
Pierre Broqua
Martin Luck
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of UY27378A1 publication Critical patent/UY27378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen composiciones farmacéuticas para el tratamiento de enfermedades dependientes de esteroides, y otras. Las composiciones son soluciones para inyección subcutánea o intramuscular, y el agente activo es un péptido antagonista de GnRH de acuerdo con la fórmula general 1, presente a una concentración suficiente como para formar un gel después de la administración.
UY27378A 2001-07-12 2002-07-11 Composición farmacéutica UY27378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117057.0A GB0117057D0 (en) 2001-07-12 2001-07-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
UY27378A1 true UY27378A1 (es) 2003-02-28

Family

ID=9918396

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27378A UY27378A1 (es) 2001-07-12 2002-07-11 Composición farmacéutica

Country Status (13)

Country Link
US (4) US20040038903A1 (es)
EP (1) EP1404357B1 (es)
JP (1) JP4845166B2 (es)
AR (1) AR036337A1 (es)
AT (1) ATE452648T1 (es)
DE (1) DE60234831D1 (es)
DK (1) DK1404357T3 (es)
ES (1) ES2338217T3 (es)
GB (1) GB0117057D0 (es)
MY (1) MY139203A (es)
PT (1) PT1404357E (es)
UY (1) UY27378A1 (es)
WO (1) WO2003006049A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
RS52966B (en) 2002-09-27 2014-02-28 Zentaris Gmbh FORM OF THE THERAPEUTIC APPLICATION OF ACTIVE PEPTIDES WITH THE LONG TERM RELEASE OF THE ACTIVE INGREDIENT
ES2555681T3 (es) 2003-10-03 2016-01-07 Thorn Bioscience, Llc Procedimiento para la sincronización de la ovulación para la fecundación programada sin detección del celo
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2120859B1 (en) * 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
BRPI1014362A2 (pt) 2009-04-23 2016-04-05 Pennatek Llc método e composição para sincronizar o tempo de inseminação
JO3550B1 (ar) * 2009-05-01 2020-07-05 Ferring Int Center Sa مركب لمعالجة سرطان البروستاتا
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
ES2808409T3 (es) 2012-11-28 2021-02-26 United Ah Ii Llc Método para sincronizar el tiempo de inseminación en cerdas primerizas
US10681261B2 (en) * 2012-11-30 2020-06-09 3I Avi, Llc Inspection system
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200486A (en) * 1878-02-19 Improvement in apparatus for attaching harness to the shafts
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2589322T3 (es) * 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US9260480B2 (en) * 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2841751A1 (en) * 2011-07-15 2013-01-24 Raymond E. Joseph Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
US20090018085A1 (en) 2009-01-15
US20040038903A1 (en) 2004-02-26
US20050245455A1 (en) 2005-11-03
AR036337A1 (es) 2004-09-01
ES2338217T3 (es) 2010-05-05
MY139203A (en) 2009-08-28
DK1404357T3 (da) 2010-05-03
JP4845166B2 (ja) 2011-12-28
DE60234831D1 (de) 2010-02-04
WO2003006049A1 (en) 2003-01-23
PT1404357E (pt) 2010-03-16
ATE452648T1 (de) 2010-01-15
US20110053846A1 (en) 2011-03-03
EP1404357B1 (en) 2009-12-23
EP1404357A1 (en) 2004-04-07
JP2005511491A (ja) 2005-04-28
GB0117057D0 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
UY27378A1 (es) Composición farmacéutica
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
SE0100568D0 (sv) Compounds
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
BRPI9708706C8 (pt) composição farmacêutica para administração intravenosa a um paciente
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DE60138572D1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
SE0100566D0 (sv) Compounds
GT200000071A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
ES2210727T3 (es) Composicion topica que contiene factor de crecimiento epidermico humano.
CO5540279A2 (es) Formulacion liofilitada de 2-metil-tieno-benzodiazepina
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150212